Mayo Clinic Laboratories > MayoComplete

MAYOCOMPLETE

Next-generation sequencing for hematologic and oncologic conditions

Every person affected by cancer needs unique care and treatment. Designed using our extensive clinical experience and informed by the latest in cancer biomarker discovery and treatments, our suite of MayoComplete next-generation sequencing panels puts patients on the right path.

24/7

24/7 access to our call center, always answered by a representative.

Education

Ongoing education, developed by Mayo Clinic experts, that covers the latest in hematology and oncology testing.

Team

A team of board-certified geneticists and genetic counselors, who are available to assist with questions related to testing options and results interpretation.

EXPERTS

Our MayoComplete suite of next-generation sequencing panels is developed, validated, and interpreted by Mayo Clinic experts from geneticists, pathologists, oncologists, and hematologists to align with guidelines.

MAYOCOMPLETE Test menu

Acute myeloid leukemia Acute myeloid leukemia
Acute myeloid leukemia

Our clinically validated testing for acute myeloid leukemia can provide critical diagnostic, prognostic, and therapeutic information for physicians.

B-cell lymphoma B-cell lymphoma
B-cell lymphoma

Offering two genetic panels to help profile B-cell lymphoma, our NGS testing evaluates dozens of genes with associations to B-cell lymphoma to help to characterize the cancer type, which can assist with differential diagnosis and targeted treatment selection.

Colorectal cancer Colorectal cancer
Colorectal cancer

Our next-generation sequencing colorectal cancer panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.

Gastrointestinal stromal tumors Gastrointestinal stromal tumors
Gastrointestinal stromal tumors

Our MayoComplete noncolorectal gastrointestinal cancer evaluation assists in diagnosis by evaluating for mutations in the PDGFRA and KIT genes.

Gynecological cancer Gynecological cancer
Gynecological cancer

We offer three MayoComplete gynecological cancer panels, including comprehensive and focused panels, that evaluate for genetic variations associated with diagnosis, prognosis, and treatment response.

Histiocytic neoplasms Histiocytic neoplasms
Histiocytic neoplasms

Including genes commonly mutated in the biologic pathways associated with histiocytic neoplasms, our focused histiocytic panel provides insights on disease origins, differential diagnosis, and therapeutic decision-making.

Liquid biopsy Liquid biopsy
Liquid biopsy

Our liquid biopsy panel is a cell-free DNA test that uses next-generation sequencing to evaluate peripheral blood for 33 genes. The assay detects for single nucleotide variants, insertions, and deletions, as well as translocations and microsatellite instability (MSI).

Lung cancer Lung cancer
Lung Cancer

Our targeted lung cancer panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.

Melanoma Melanoma
Melanoma

Our melanoma panel identifies variants in 17 genes associated with diagnosis, prognosis, and treatment guidance. Offering increased sensitivity for heightened accuracy, our melanoma evaluation includes full exonic sequencing of the genes, as opposed to evaluating only targeted areas.

Neuro-oncology Neuro-oncology
Neuro-oncology

Our next-generation sequencing neuro-oncology panel evaluates for mutations and rearrangements in 160 genes, including most abnormalities described by the World Health Organization 2021 classifications.

Pan cancer Pan cancer
Pan cancer

Our 514-gene panel analyzes mutations, rearrangements, and/or amplifications as well as evaluates tumor mutation burden status and microsatellite instability.

Plasma cell myeloma Plasma cell myeloma
Plasma cell myeloma

Focused on genes implicated in multiple myeloma, our 26-gene panel can help characterize diagnosis, monitor for disease progression and transition, and clarify treatment targets. Our assay involves a pre-analytical step of cell sorting and only tests DNA from the plasma cell population, which increases testing sensitivity.

Sarcoma Sarcoma
Sarcoma

Our comprehensive sarcoma fusion panel includes 169 genes and assesses mutations and fusions described in more than 50 types of soft tissue, bone, and other mesenchymal tumors. The panel is designed to provide the most comprehensive analysis by including 124 gene fusion pairs, 274 fusion variants, and novel gene partner detection.

T-cell lymphoma T-cell lymphoma
T-cell Lymphoma

Our novel MayoComplete T-cell lymphoma panel examines 26 genes with known diagnostic, prognostic, or therapeutic association in a number of T-cell lymphoma subtypes, including angioimmunoblastic T-cell lymphoma and large granular lymphocytic leukemia. 

Urologic cancer Urologic cancer
Urologic cancer

Our three focused MayoComplete next-generation sequencing urology panels were carefully curated by a collaborative team of clinical experts, geneticists, and genetic counselors to include only clinically relevant genes. They include testing for kidney cancer, bladder and prostate cancer, and fibromyomatous RCC.

The testing you need - all in one place

Our robust suite of MayoComplete oncology and hematology testing uses next-generation sequencing to identify and evaluate the presence of mutations. Our testing approach includes:

  • Comprehensive panels with increased sensitivity and improved accuracy, designed to help you make informed decisions on your patients’ cancer care.
  • Complementary microarray, FISH, and IHC testing, enabling full-spectrum testing in one laboratory.

Personalized answers for patients

Ongoing, rapid advancements in cancer biomarker discovery and treatments, combined with the need for genetic testing to determine eligibility for certain therapies, require a dynamic testing approach that meets the needs of every patient. Each MayoComplete panel:

  • Provides diagnostic, prognostic, and therapeutic insights, including the latest targeted immunotherapies.
  • Is designed to ensure each patient receives the right test and personalized answers to guide their cancer journey.
News and updates

The latest

Dr. Dong Chen and Dr. Sounak Gupta join Becker’s Healthcare Podcast to discuss molecular testing in cancer care

Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.

Learn more
MayoComplete Next-Generation Sequencing: Oncology Subpanels

In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.

Melanoma panel provides more tumor information

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Colorectal panel provides detailed cancer information

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Focused lung panel informs the use of targeted cancer therapies

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

NGS for Myeloid Neoplasm Evaluation

In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.

Patient-focused pragmatism: The Mayo Clinic innovation model

In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.

A “sandbox” for innovation: The Advanced Diagnostics Laboratory

Mayo Clinic’s Advanced Diagnostics Laboratory (ADL) is a visionary space designed to foster innovation. The ADL has a direct impact on patient lives, bringing promising tests and services to patients at Mayo and around the world.

MayoComplete Solid Tumor Panel

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

Resources
View now Hematology, oncology, and hereditary test selection guide
View MayoComplete solid tumor testing negative report example
View MayoComplete solid tumor testing positive report example
Download Tissue requirements for solid tumor NGS
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.